Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 126.74% | -1,046.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 126.74% | -1,046.07% | |||
| Cost of Revenue | 109.14% | -686.26% | |||
| Gross Profit | -82.72% | 473.34% | |||
| SG&A Expenses | 282.86% | -19.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 159.84% | -383.74% | |||
| Operating Income | -229.40% | 214.82% | |||
| Income Before Tax | -416.14% | 154.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -416.14% | 154.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -416.14% | 154.26% | |||
| EBIT | -229.40% | 214.82% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -417.24% | 153.70% | |||
| Normalized Basic EPS | -422.22% | 152.94% | |||
| EPS Diluted | -417.24% | 153.70% | |||
| Normalized Diluted EPS | -422.22% | 152.94% | |||
| Average Basic Shares Outstanding | -0.21% | 0.22% | |||
| Average Diluted Shares Outstanding | -0.21% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
